Carrera Capital Advisors Gilead Sciences, Inc. Transaction History
Carrera Capital Advisors
- $427 Billion
- Q4 2024
A detailed history of Carrera Capital Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Carrera Capital Advisors holds 33,400 shares of GILD stock, worth $3.69 Million. This represents 0.72% of its overall portfolio holdings.
Number of Shares
33,400
Previous 25,546
30.74%
Holding current value
$3.69 Million
Previous $2.14 Billion
44.05%
% of portfolio
0.72%
Previous 0.52%
Shares
3 transactions
Others Institutions Holding GILD
# of Institutions
2,091Shares Held
1.02BCall Options Held
8.73MPut Options Held
9.63M-
Black Rock Inc. New York, NY121MShares$13.3 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12.8 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.92 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.67 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.4 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $138B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...